R&D
NIPER Raebareli–Roche tie-up signals big push for India’s pharma innovation future
The partnership is designed to close the gap between classroom learning and real-world pharmaceutical practice
- By IPP Bureau
| March 20, 2026
In a move aimed at sharpening India’s edge in pharmaceutical innovation, the National Institute of Pharmaceutical Education and Research Raebareli has inked a key partnership with Roche Pharma India to boost industry-ready education and cutting-edge research.
The Memorandum of Understanding (MoU), signed at Shastri Bhawan in New Delhi, brings together academia and industry at a time when India is pushing to move beyond volume-driven growth toward high-value innovation in the biopharma sector. The agreement was formalized in the presence of Manoj Joshi, Secretary in the Department of Pharmaceuticals under the Ministry of Chemicals and Fertilizers.
At its core, the partnership is designed to close the gap between classroom learning and real-world pharmaceutical practice. Students and professionals will gain exposure to evolving regulatory frameworks, emerging technologies, and industry expectations through joint initiatives.
These include a specialized certificate programme in regulatory affairs, as well as guest lectures led by industry experts focusing on fast-evolving areas such as AI-driven drug research, development pipelines, and healthcare innovation.
Highlighting the urgency of such collaborations, Joshi said India must deepen its expertise in critical areas to remain globally competitive. He stressed that “India needs to strengthen its capabilities in regulatory sciences, biologics and AI in pharmaceuticals to achieve a sustained global competitive advantage and consolidate its global position,” adding that “academia-industry collaborations are critical to fulfilling these aspirations.”
The tie-up dovetails with broader national ambitions, including the government’s push under the Viksit Bharat vision and the Biopharma Shakti mission, both aimed at transforming India into a global hub for high-value pharmaceutical innovation.
Officials say the initiative is a decisive step toward building a future-ready workforce while accelerating sustainable growth across India’s life sciences ecosystem.